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Abstract
A cluster of 3 facial Mycobacterium chelonae infections occurred after cosmetic dermal filler 
injections at a plastic surgery clinic. Pulsed-field gel electrophoresis showed that M chelonae 
isolated from the clinic tap water were identical to the patient wound isolates. Review of injection 
procedures identified application of nonsterile ice to the skin prior to injection as a possible source 
of M chelonae. Surveys of regional laboratories and a national plastic surgery listserv identified no 
other cases related to the injection of this brand of dermal filler. This is the first report of 
cutaneous M chelonae infections following the injection of dermal fillers. It adds to a growing 
body of literature on postinjection M chelonae infections and reinforces the importance of optimal 
skin disinfection steps prior to percutaneous procedures.
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The injection of filler materials such as hyaluronic acid into the subcutaneous tissue of the 
face has become one of the most commonly performed cosmetic procedures. Unlike 
injections for medications or vaccinations, however, the filler material is intended to remain 
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at the injection site for an extended period of time. In this respect, filler materials resemble 
implants, and these injections may deserve strict adherence to sterile technique.
Nontuberculous mycobacteria (NTM) are ubiquitous in the environment and are known to 
exist in municipal and hospital water systems.1–4 They can cause skin and soft tissue 
infections in both health care and community settings.5–9 Nontuberculous mycobacteria are 
classified into 4 groups based on their colony morphology, growth rate, and pigment. One 
major pathogenic group is the rapidly growing mycobacteria, of which the main clinically 
relevant species include Mycobacterium chelonae, Mycobacterium abscessus, and 
Mycobacterium fortuitum.3,9 Infection presents as skin nodules, with or without drainage or 
discoloration, usually 3 to 6 weeks after inoculation.10 Outbreaks of M chelonae cutaneous 
infections associated with surgical or percutaneous procedures are well described and 
generally occur when tap water somehow contaminates the procedure.3,4,11–19 Although 
injection-related NTM infections are also described, no such infections have been reported 
in the context of commercially prepared dermal filler products.
After 2 cases of M chelonae facial infection following dermal filler injection were confirmed 
(and another case presumed) from a single aesthetic medicine clinic, we undertook an 
investigation to identify the source of infection and to determine whether there were other 
unreported cases.
CASE REPORTS
For the purposes of this investigation, we defined a confirmed case as a patient with a skin/
soft-tissue infection and a positive skin-aspirate culture for M chelonae following dermal 
filler injections between October 2008 and January 2009. We defined a presumptive case as 
an individual with a clinical presentation consistent with NTM skin infection and response 
to empiric treatment for mycobacterium following dermal filler injection during the same 
time period.
Confirmed case 1 was a 48-year-old, otherwise healthy woman who underwent multiple 
facial injections in October 2008 from a syringe of Juvederm Ultra Plus (Allergan, Inc, 
Irvine, California) that had previously been split into 2 portions, as was common at the 
facility where she was treated. She sought medical attention approximately 24 hours later at 
a local emergency department, complaining of redness at the injection site. She was treated 
symptomatically and did not have further medical follow-up until 3 weeks later, when she 
sought treatment for facial redness, swelling, and drainage. Rapidly growing Mycobacterium 
species, later identified as M chelonae, was isolated from an aspirate of the left cheek. Under 
the care of an infectious disease consultant, she was treated with clarithromycin and 
linezolid by mouth and intravenous amikacin. Because of progressive leukopenia, the 
linezolid was discontinued after 4 weeks; therapy was completed with amikacin for 12 
weeks and clarithromycin for 6 months. At the conclusion of therapy, the lesion had 
resolved without scarring.
Confirmed case 2 was a 46-year-old, otherwise healthy woman who underwent facial 
injections with an unopened syringe of Juvederm Ultra Plus in November 2008. Eighteen 
days later, she reported the onset of facial redness and itching. An aspirate of the right cheek 
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grew M chelonae. The same infectious disease consultant treated this case in the first month 
with clarithromycin and moxifloxacin; subsequently, the patient received 2 months of 
linezolid plus 3 months of azithromycin. Her lesions resolved by the conclusion of antibiotic 
therapy.
Presumptive case 1 was a 54-year-old, otherwise healthy woman who underwent injections 
of Juvederm Ultra from an unopened syringe in November 2008. Two weeks after the 
injections, she developed redness, warmth, swelling, and changes in skin texture at the 
injection site. A facial aspirate was obtained; mycobacterial cultures were sterile and routine 
culture demonstrated only Propionibacterium species. Signs and symptoms resolved after 4 
months of treatment with azithromycin plus moxifloxacin.
DISCUSSION
To determine whether additional cases had occurred at the clinic where the first 2 cases were 
confirmed, we reviewed appointment logs for all visits coded for dermal filler or other facial 
injections. Using a standardized questionnaire, phone interviews were conducted with all 
patients who received a dermal injection at this facility between October 1 and December 
31, 2008. Twenty-eight unique individuals, including the original 3 patients described 
above, received Juvederm Ultra or Juvederm Ultra Plus at the clinic in October and 
November 2008. We interviewed 13 (52%) of the 25 other patients but identified no 
additional cases. We also interviewed 8 (50%) of the 16 additional patients who received an 
injection of other products within 1 day of the injection date in the confirmed cases. Among 
these 8, 1 patient who received a Restylane (Medicis, Inc, Scottsdale, Arizona) injection was 
suspected of having an NTM infection but to our knowledge did not seek medical attention.
To address our concern that a commercially distributed dermal filler product might be 
contaminated with M chelonae, we contacted 30 local laboratories in the region that perform 
mycobacterial culture. Each lab was asked to review its records to identify cultures growing 
M chelonae from June through December 2008; no isolates from wound sources were 
identified.
To assess whether other clusters had been noted nationally, we posted notices on listservs 
likely to be seen by plastic surgeons, dermatologists, and infectious disease providers. We 
asked readers to report confirmed or presumptive cases of soft tissue infection with M 
chelonae following dermal filler injection; we received no replies of other infections 
associated with these products. We also contacted the manufacturer of Juvederm products, 
but it reported no other clusters of infections.
Environmental Investigation
Public health staff visited the clinic site to assess procedures, review lot numbers, and 
collect specimens for laboratory testing. Environmental specimens collected on December 
30, 2008, included tap water from the faucet of the primary exam treatment room; water 
from the ice-machine intake, as well as swabs of the intake and interior of the ice machine; 
samples of anesthetic creams stored in bulk containers; samples of topical disinfectants, 
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including isopropyl alcohol and an ammonium/phenolic compound; samples of household 
disinfectant for nonhuman surfaces; and open bottles of saline solution from the exam room.
Our chart review of the 2 confirmed cases found that those patients were injected with 
Juvederm Ultra Plus from different lot numbers. The procedure records, however, did not 
detail the use of specific antiseptics, anesthetics, or the sequence in which topical products 
were used at each visit. A typical injection procedure was described as beginning with the 
application of EMLA (App Pharmaceuticals, Schaumberg, Illinois) or a similar topical 
anesthetic for 20 to 40 minutes. Subsequently, 70% isopropyl alcohol from multiuse 
containers was applied to intended injection sites for disinfection. In response to the first 
case, the disinfectant was changed to a quaternary ammonium/ phenolic compound in the 
beginning of November, suggesting that the second confirmed case received a different 
topical disinfectant. Next, most patients opted to apply ice contained in exam gloves or 
Ziplock-type bags to the intended injection site for further anesthetic effect. Finally, up to 50 
injections were administered per session using 27- or 30-gauge needles; needles were 
changed every 3 to 4 injections, when they became dull. Although most needles were 
supplied with the dermal filler product, the clinic also stocked needles. After the injections, 
ice was typically again applied to the skin, followed by topical hydrocortisone and vitamin 
K cream. Both the topical anesthetics and hydrocortisone were purchased in bulk and 
repackaged in smaller containers. In response to the first case, the hydrocortisone cream and 
vitamin K stocks were discarded. The practitioner wore nonsterile gloves during dermal 
filler procedures.
Laboratory Studies
Environmental specimens obtained from the clinic were sent to the Oregon State Public 
Health Laboratory for mycobacterial culture. The water samples were filtered through a 0.2-
μm filter and the residue was resuspended in a smaller volume. The resuspended sediment 
was then plated on Middlebrook 7H10 agar. Mycobacterium species grew from the tap water 
obtained from the faucet in the exam room. All of the other environmental specimens, 
including the swabs from the ice machine, were negative for acid-fast bacilli. Of note, the 
ice machine had been replaced 1 week prior to swabbing.
The specimens from the confirmed cases and the environmental isolates were forwarded 
from the original laboratory to the Centers for Disease Control and Prevention (CDC) for 
identification by high-performance liquid chromatography (HPLC), full-length 16S rRNA 
and rpoB gene sequencing, and comparison by pulsed-field gel electrophoresis. Mycolic 
acid analysis of the isolates with HPLC yielded profiles representative of the M chelonae–M 
abscessus complex. All of the isolates exhibited 100% 16S rRNA and rpoB gene sequence 
similarity to the GenBank M chelonae strain ATCC 19237. In addition, the 3 environmental 
isolates and the 2 clinical isolates matched when compared by pulsed-field gel 
electrophoresis, suggesting that the tap water was the source of contamination (Figure 1).
Our site investigation and procedural review suggested a potential mechanism for the 
introduction of contamination: ice made from tap water on site was applied after disinfection 
of the skin but before injection of the filler. Although the ice was sealed in Ziplock bags, 
leakage may have occurred, contaminating the skin surface and allowing for intradermal 
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inoculation during the procedure. Other opportunities for tap water exposure of the injection 
site include rinsing of nonsterile equipment used in the procedure or the practitioner’s 
contamination of his non-sterile gloves.
The multiuse containers used to store topical agents could also have served as a source for M 
chelonae colonization. Although cultures for the topical disinfectant and anesthetic were 
negative, our samples were not taken from containers present on the days that the confirmed 
patients received their injections. Interestingly, a growing body of literature describes 
resistance and selection of more pathogenic strains of nontuberculous mycobacteria, 
including M chelonae in commonly used antiseptic agents such as quaternary ammonium 
disinfectants of the type used in the practice.20
Although the infections described in this report resolved with prolonged antibiotic therapy, 
their occurrence highlights the necessity for sterile injection practices with such products. 
The Juvederm Ultra Plus guidelines identify antisepsis as the step immediately prior to 
injection of the product, and application of ice is suggested for pain control after, not prior 
to, injection.21 Unlike most medicinal injections that are absorbed into tissues in short order, 
filler materials are intended to remain where injected indefinitely. For injections that rapidly 
diffuse in the subcutaneous tissues, a simple swab of the skin suffices as a disinfection step. 
On the other hand, longevity of these filler substances creates a volume of material that is 
less accessible to the immune system.22 Stricter adherence to antisepsis may need to be 
required for intradermal filler injections. Our findings suggest precautionary standards that 
(1) proscribe skin exposure to tap water immediately before and after an injection procedure, 
(2) standardize a consistent skin disinfection step immediately prior to injection, and (3) 
require documentation of disinfection steps and other topical treatments in patient medical 
records.
Only Mycobacterium simiae has been previously reported in association with a similar 
cosmetic intradermal microinjection procedure associated with an unlicensed compound.23 
To our knowledge, this is the first report of a rapidly growing mycobacterial infection 
associated with a dermal filler injection.
This retrospective investigation is subject to several limitations. First, the environmental 
investigation was incomplete. Because of the long incubation period of NTM infections, we 
did not become aware of this cluster until many weeks after the clinic visits. By the time the 
investigation began, we could not test the bulk anesthetics, disinfectants, and other topical 
products in use at the time of the dermal filler injections since they had been discarded. In 
addition, the ice machine in use at the time of the injections had also been replaced. Second, 
the patient medical records lacked sufficient detail for a case control study; we were unable 
to explore procedure-related risk factors, such as anesthetic choice or injection details, or 
patient-related risk factors, such as concurrent immunological or dermatological conditions 
among dermal filler recipients. Finally, although we did identify M chelonae in the clinic 
water supply, this organism is common and its identification could be coincidental, although 
coincidence is less likely since the environmental and clinical isolates were identical species 
by mycolic acid analysis and gene sequencing.24–26 Most important, the isolates matched by 
pulsed-field gel electrophoresis, an established standard for distinguishing M chelonae.27
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CONCLUSIONS
These 3 cases of M chelonae contamination illustrate a need to optimize antisepsis and 
minimize water exposure during simple cosmetic procedures such as intradermal injections. 
Providers should recognize that tap water, ice made from tap water, and open multiuse 
containers of aqueous solutions can be contaminated by rapidly growing mycobacteria.
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Figure 1. 
Pulsed-field gel electrophoresis patterns of clinical and environmental Mycobacterium 
chelonae isolates.
Rodriguez et al. Page 8
Aesthet Surg J. Author manuscript; available in PMC 2015 October 24.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
